Literature DB >> 33922865

SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits.

Giovanna Leoncini1, Elisa Russo1, Elisabetta Bussalino1, Cecilia Barnini1, Francesca Viazzi1, Roberto Pontremoli1.   

Abstract

In recent years, following the publication of results from several RCTs, first on cardiovascular and more recently on renal outcomes, SGLT2is have become the standard of care to prevent diabetic kidney disease and slow its progression. This narrative review focuses on biological mechanisms, both renal and extrarenal, underlying kidney protection with SGLT2is. Furthermore, data from cardiovascular as well as renal outcome trials, mostly conducted in diabetic patients, are presented and discussed to provide an overview of current uses as well as the future therapeutic potential of these drugs.

Entities:  

Keywords:  SGLT2 inhibitors; kidney disease; kidney protection

Year:  2021        PMID： 33922865     DOI： 10.3390/ijms22094441

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN： 1422-0067            Impact factor:   5.923


  54 in total

Review 1.  The role of the endothelial glycocalyx in advanced age and cardiovascular disease.

Authors:  Daniel R Machin; Tam Tt Phuong; Anthony J Donato
Journal:  Curr Opin Pharmacol       Date:  2019-05-18       Impact factor: 5.547

2.  The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.

Authors:  Jens Jordan; Jens Tank; Karsten Heusser; Tim Heise; Christoph Wanner; Martina Heer; Sreeraj Macha; Michaela Mattheus; Søren S Lund; Hans J Woerle; Uli C Broedl
Journal:  J Am Soc Hypertens       Date:  2017-07-21

3.  KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.

Authors:  Charmaine E Lok; Thomas S Huber; Timmy Lee; Surendra Shenoy; Alexander S Yevzlin; Kenneth Abreo; Michael Allon; Arif Asif; Brad C Astor; Marc H Glickman; Janet Graham; Louise M Moist; Dheeraj K Rajan; Cynthia Roberts; Tushar J Vachharajani; Rudolph P Valentini
Journal:  Am J Kidney Dis       Date:  2020-03-12       Impact factor: 8.860

4.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

5.  Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.

Authors:  Yochai Birnbaum; Mandeep Bajaj; Hsiu-Chiung Yang; Yumei Ye
Journal:  Cardiovasc Drugs Ther       Date:  2018-04       Impact factor: 3.727

Review 6.  SGLT2 inhibitors: their potential reduction in blood pressure.

Authors:  George Maliha; Raymond R Townsend
Journal:  J Am Soc Hypertens       Date:  2014-11-12

Review 7.  JAK inhibition in the treatment of diabetic kidney disease.

Authors:  Frank C Brosius; Katherine R Tuttle; Matthias Kretzler
Journal:  Diabetologia       Date:  2016-06-22       Impact factor: 10.122

8.  Changes in diabetes-related complications in the United States, 1990-2010.

Authors:  Edward W Gregg; Yanfeng Li; Jing Wang; Nilka Rios Burrows; Mohammed K Ali; Deborah Rolka; Desmond E Williams; Linda Geiss
Journal:  N Engl J Med       Date:  2014-04-17       Impact factor: 91.245

9.  Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors.

Authors:  Aviram Kogot-Levin; Liad Hinden; Yael Riahi; Tal Israeli; Boaz Tirosh; Erol Cerasi; Ernesto Bernal Mizrachi; Joseph Tam; Ofri Mosenzon; Gil Leibowitz
Journal:  Cell Rep       Date:  2020-07-28       Impact factor: 9.423

Review 10.  The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Authors:  William G Herrington; David Preiss; Richard Haynes; Maximilian von Eynatten; Natalie Staplin; Sibylle J Hauske; Jyothis T George; Jennifer B Green; Martin J Landray; Colin Baigent; Christoph Wanner
Journal:  Clin Kidney J       Date:  2018-10-25
View more
  2 in total

1.  SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.

Authors:  Danii L S Suijk; Michaël J B van Baar; Erik J M van Bommel; Zainab Iqbal; Merle M Krebber; Volker Vallon; Daan Touw; Ewout J Hoorn; Max Nieuwdorp; Mark M H Kramer; Jaap A Joles; Petter Bjornstad; Daniël H van Raalte
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-23       Impact factor: 10.614

Review 2.  Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications.

Authors:  Virginia Bellido; Julia Martínez; Fernando Calvo; Aida Villarroel; Edurne Lecumberri; Juan Moreno; Carlos Morillas; Silvia Rodrigo; Aitziber Izarra; Albert Lecube
Journal:  Diabetes Ther       Date:  2022-03-25       Impact factor: 3.595
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.